BI
CRL icon

Binnacle Investments’s Charles River Laboratories CRL Stock Holding History

Binnacle Investments’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$313 Buy
+2
New +$318 ﹤0.01% 893

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Binnacle Investments's CRL Position: Q3 2025 in Review

Binnacle Investments opened a new position in Charles River Laboratories (CRL) in Q3 2025: 2 shares worth $313. The stake represents ﹤0.01% of the portfolio and ranks #893 among its holdings.

554 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Binnacle Investments held 2 shares of Charles River Laboratories worth $313 as of Q3 2025.
  • Charles River Laboratories was a new Binnacle Investments position in Q3 2025.
  • Charles River Laboratories made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #893 holding.
  • 554 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.